DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Full textbookMLAMSRAGP

Pityriasis rubra pilaris awareness

Recognise the distinctive follicular, palmoplantar and island-sparing pattern of pityriasis rubra pilaris, confirm rare disease thoughtfully, protect erythrodermic physiology, and refer for specialist treatment.

!
Erythrodermic PRP

Pityriasis rubra pilaris can generalise into erythroderma with shivering, temperature dysregulation, fluid loss, oedema, infection and cardiorenal strain.

Action: Arrange immediate same-day dermatology and acute medical assessment, check ABCDE and fluid balance, and begin gentle barrier support while excluding infection, drug reaction and other erythrodermas.

Open the sections you need. The overview is shown first.
01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Pityriasis rubra pilaris is uncommon enough that delayed or changing diagnosis is expected. Awareness rests on recognising the combination of follicular roughness, coalescing cephalocaudal plaques, spared islands and waxy palms or soles.

Colour terminology must not dominate. Orange-red is classic, but deeply pigmented skin may show brown, violaceous or less obvious colour while keratotic follicular papules and sharp islands remain palpable and visible.

Management depends on extent and physiology. Local treatment improves comfort; extensive PRP belongs with dermatology because systemic therapies are often off-label, evidence is limited and erythroderma can become medically unstable.

Key points

  • PRP is a rare inflammatory keratinisation disorder characterised by rough follicular papules, coalescing orange-red or brown-red scaly plaques, islands of sparing and waxy palmoplantar keratoderma.
  • Classic adult PRP often starts on scalp or face and spreads downwards; orange colour may be subtle in deeply pigmented skin, so texture, follicular plugging and spared islands are more reliable.
  • Palms and soles become thick, orange or waxy and fissured; pain, walking and hand function are essential severity outcomes.
  • Diagnosis is clinical with dermatology confirmation; biopsy can support the pattern and exclude psoriasis, drug eruption or lymphoma, but no blood test confirms PRP.
  • Classic adult type has the most favourable natural history, with BAD reporting spontaneous clearance in up to 80% within three years, while atypical and familial forms may persist.
  • Limited disease uses regular emollient, keratolytic and site-appropriate topical corticosteroid for symptoms; these may reduce inflammation without shortening the whole disease course.
  • Extensive disease requires specialist treatment, commonly off-label acitretin or methotrexate and sometimes phototherapy or biologic therapy after careful diagnosis and monitoring.
  • Erythroderma with shivering, fluid loss or systemic instability requires immediate same-day specialist assessment and acute barrier-failure care.
02AetiologyUnderlying causes, associations and risk factors, with why each one matters.
01

Usually sporadic inflammation

PRP is a rare inflammatory keratinisation disorder whose cause is usually unknown. It is not infectious and affects people of all racial groups and sexes.

02

Occasional familial disease

Most cases are not inherited, but familial juvenile forms occur and can involve CARD14-related pathways. Childhood onset and affected relatives justify specialist genetic consideration rather than routine testing.

03

Six clinical types

Classification includes classic and atypical adult, three juvenile patterns and HIV-associated PRP. Type identifies expected distribution and natural history but does not replace assessment of current severity.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.
  1. 1
    Disordered keratinisation

    Abnormal epidermal differentiation produces scale, follicular keratin plugs and thick waxy palmoplantar skin. Inflammation adds colour, itch and progressive plaque coalescence.

  2. 2
    Follicular-to-plaque evolution

    Keratin plugs begin around hairs, then papules merge into orange-red or brown-red plaques that often spread from head downward while leaving sharply defined islands of unaffected skin.

  3. 3
    Barrier failure in erythroderma

    When most skin is involved, impaired temperature control and water, electrolyte and protein loss create systemic illness. Extent converts a rare rash into an acute medical problem.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.
Follicular keratotic papules

Small rough papules centre on hair follicles, especially dorsal fingers, elbows, knees or trunk. Running a hand lightly across skin may reveal the sandpaper texture before colour is striking.

Cephalocaudal plaques

Classic adult disease often begins on scalp or face and spreads downward as scaly papules merge. The borders can be sharply demarcated despite progressive generalisation.

Islands of sparing

Discrete patches of normal-appearing skin remain within large confluent plaques. This striking geometry favours PRP over many other erythrodermas but is not independently diagnostic.

Waxy palmoplantar keratoderma

Palms and soles become diffusely thick, smooth, orange-yellow or waxy and develop painful fissures. Record walking, grip and secondary infection rather than describing appearance alone.

Skin-tone-aware colour

Plaques may be deep brown, violaceous or subtly warm-toned rather than visibly orange-red. Compare with uninvolved islands and prioritise scale, follicular texture, heat and symptoms.

Erythrodermic deteriorationRed flag

Near-total involvement with shivering, temperature change, oedema, tachycardia, oliguria or breathlessness indicates barrier failure and needs immediate acute care.

Red flags requiring action

  • Near-total skin inflammation with shivering, fever or hypothermia, tachycardia, oedema, reduced urine output or breathlessness requires emergency assessment.
  • Skin pain, mucosal erosions, dusky targets, blistering or a recent high-risk medicine suggests severe drug reaction rather than uncomplicated PRP.
  • Rapidly spreading warmth, purpura, focal disproportionate pain or haemodynamic compromise raises concern for invasive infection and needs immediate sepsis and surgical assessment.
  • Marked palmoplantar fissuring that prevents walking or hand use, nutritional compromise or severe distress warrants expedited specialist support even without erythroderma.
05InvestigationsWhat to request, why it matters and how to interpret it.
Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

  1. 01
    First-line full skin, scalp, nail and mucosal examinationFirst stepFirst line
    Why
    Identify follicular papules, direction of spread, islands of sparing, palmoplantar keratoderma and features of competing erythrodermas.
    Interpretation and limitations
    The constellation supports PRP, but mucosal erosions, blistering, marked lymphadenopathy or a drug timeline shifts urgency and differential.
  2. 02
    Skin biopsy from representative active disease
    Why
    Support PRP and exclude psoriasis, cutaneous lymphoma, drug eruption or another keratinisation disorder.
    Interpretation and limitations
    Histology can be suggestive rather than definitive, especially early. Select an untreated follicular plaque with dermatology input and provide the clinical pattern and differential.
  3. 03
    Physiological and laboratory assessment in extensive disease
    Why
    Detect temperature disturbance, dehydration, infection, renal injury, electrolyte loss and hypoalbuminaemia.
    Interpretation and limitations
    Trend observations, urine output, weight, blood count, CRP, renal and liver profile, calcium, magnesium and albumin; results measure complications rather than confirm PRP.
  4. 04
    Targeted HIV testing
    Why
    Assess relevant risk or an atypical severe follicular presentation because HIV-associated PRP is a recognised type.
    Interpretation and limitations
    Offer with consent and explain implications; a positive result redirects comprehensive HIV care, while negative testing does not settle the skin diagnosis.
  5. 05
    Mycology or scabies testing when indicated
    Why
    Exclude treatable infection in asymmetric, crusted or immunosuppressed presentations before escalating immunosuppression.
    Interpretation and limitations
    Take good-quality scale or mite samples from active sites. Positive colonising organisms must still be reconciled with the entire morphology.
  6. 06
    Baseline systemic-treatment safety panel
    Why
    Assess blood count, renal and liver function, lipids, pregnancy status, infection and agent-specific risks before off-label systemic therapy.
    Interpretation and limitations
    No universal PRP regimen exists; the selected medicine defines monitoring, contraindications and response point, and one specialist team must own results.
06Differential diagnosisRealistic alternatives and the features that help distinguish them.
01

Psoriasis

Psoriasis can resemble PRP, including erythroderma. Follicular papules, orange waxy palmoplantar keratoderma and islands of sparing favour PRP, but overlap often requires histology and longitudinal review.

02

Severe eczema or drug eruption

Eczema is usually more exudative or lichenified; drug erythroderma follows an exposure timeline and may have facial oedema, eosinophilia or organ injury. Mucosal blistering redirects urgently.

03

Cutaneous lymphoma

Persistent atypical erythroderma, disproportionate itch, nodes, palmoplantar change or abnormal blood findings can indicate cutaneous T-cell lymphoma. Multiple biopsies and specialist staging may be needed.

04

Keratinisation disorders

Ichthyosis, keratoderma syndromes, follicular keratoses and Darier disease can overlap, especially in juvenile or longstanding atypical forms. Age at onset and family pattern refine classification.

05

Crusted infection

Crusted scabies or dermatophyte infection can generalise in immunosuppression. Contacts, burrows, scrapings and microscopy help, while sepsis features require treatment before final taxonomy.

07ManagementImmediate care, first-line treatment, alternatives and escalation.
01First-lineConfirm the rare diagnosisFirst stepFirst lineFollicular papules, spared islands and palmoplantar keratoderma suggest PRP without physiological instability.
  1. 1Document onset, direction of spread, family and medicine history, HIV risk, full morphology and functional impact across skin tones.
  2. 2Refer to dermatology for confirmation and select a representative biopsy when psoriasis, drug eruption, lymphoma or inherited keratinisation disease remains plausible.
  3. 3Explain uncertainty and natural history honestly: classic adult disease often clears spontaneously, but subtype and treatment response vary and review may refine the label.
02Local careReduce scale, pain and fissuringLimited disease or supportive treatment alongside specialist systemic care.
  1. 1Use generous emollient and soap substitute, protect fissures and consider a keratolytic on thick palms or soles while avoiding inflamed, cracked or large areas that increase absorption.
  2. 2Apply a site-appropriate topical corticosteroid for a short defined course to active plaques; topical treatment may relieve inflammation without changing overall duration.
  3. 3Address footwear, hand protection, pain, work and mobility, and culture or treat infection only when clinical evidence supports it.
03EscalationExtensive specialist treatmentEscalationProgressive, widespread, functionally severe or topical-resistant PRP without acute barrier failure.
  1. 1Reconfirm diagnosis, subtype and baseline safety, discussing limited evidence and off-label status before systemic treatment.
  2. 2Dermatology commonly considers acitretin or methotrexate; phototherapy or targeted biologic therapy may be used in selected refractory disease under a documented protocol.
  3. 3EscalationSet a time-limited response goal and medicine-specific blood, infection and reproductive monitoring; avoid escalating several agents without a clear attribution plan.
04EmergencyErythrodermic barrier supportNear-generalised disease with systemic symptoms, abnormal observations, oedema or reduced urine.
  1. 1Arrange immediate same-day dermatology and acute medical assessment, monitor ABCDE, temperature, weight, input-output and cardiorenal status.
  2. 2Use gentle bland emollient, non-adhesive dressings, warmth and carefully titrated fluid or electrolyte replacement while assessing infection and thrombosis risk.
  3. 3Review recent and stopped medicines, culture when indicated and exclude severe drug reaction, sepsis and other erythrodermas; do not wait for biopsy before stabilising physiology.
Key medicines and prescribing safety3 treatments · regimens, roles and cautions
Restores comfort and supports the barrier in local and extensive PRP, although it does not control systemic inflammatory disease alone.

Emollient or soap substitute

Apply generously and frequently to dry or fissured skin and use as a wash substitute, coordinating applications with active treatment and non-adhesive dressings.

Fabric and hair contamination increases fire severity even after drying; avoid flames and smoking, wash fabrics frequently, prevent slips and stop additives that sting erythrodermic skin.

Potent topical corticosteroid used symptomatically for limited steroid-responsive inflammation; PRP use is off-label and does not establish the diagnosis.

Betamethasone valerate 0.1% cream or ointment

Apply thinly to appropriate active plaques once or twice daily for up to 4 weeks, then reduce frequency or step down after improvement.

Avoid face, flexures, widespread erythroderma, untreated infection and unplanned occlusion; reassess diagnosis if worse or unimproved within 2 to 4 weeks.

Common specialist off-label systemic option for extensive PRP after clinical and histological assessment; evidence is limited and response varies.

Acitretin for extensive PRP

Specialist SmPC guidance starts 25 or 30 mg orally once daily with food for 2 to 4 weeks, then adjusts to response and tolerability; maximum 75 mg daily.

Highly teratogenic with pregnancy prevention and testing for 3 years after stopping where pregnancy is possible; monitor liver and lipids, avoid tetracyclines and excess vitamin A, and counsel on dryness.

08ComplicationsImportant consequences, why they occur and why they matter clinically.
01

Erythrodermic physiology

Widespread disease causes dehydration, electrolyte loss, hypoalbuminaemic oedema, temperature disturbance and high-output cardiac stress. Older or cardiorenal patients are especially vulnerable.

02

Painful palmoplantar fissures

Waxy thickening splits under load and can severely impair gait, grip, work and self-care. Deep fissures also create portals for secondary bacterial infection.

03

Secondary infection

Barrier disruption and systemic immunomodulation increase bacterial, fungal and viral infection risk. Culture when clinically indicated but distinguish colonisation from invasive disease.

04

Treatment toxicity

Retinoids, methotrexate and biologic therapy are often off-label for PRP and bring reproductive, hepatic, lipid, marrow and infection risks. Monitoring follows the selected agent and protocol.

05

Psychological burden

Rarity, diagnostic delay, visible scale, odour, pain and unpredictable course can cause isolation and low mood. Explicit validation and access to support are part of clinical care.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.
  • Track extent, new follicular papules, spared islands, palmoplantar fissures, temperature, weight and patient-valued walking or hand function rather than colour alone.
  • In erythroderma, monitor observations, core temperature, urine output, fluid balance, electrolytes, renal function, albumin, infection and cardiorespiratory status until stable.
  • For systemic treatment, follow the selected agent's blood, lipid, liver, renal, infection and reproductive schedule with a named prescriber and rapid action on abnormal results.
  • Revisit diagnosis when treatment response is paradoxical, nodes or blood abnormalities appear, mucosa becomes involved or plaques lose the expected follicular and island-sparing pattern.
  • Assess pain, sleep, work, mobility, mood and isolation; connect the person with credible rare-disease support while keeping clinical advice grounded in specialist care.
10Special situationsVariants, exceptions and circumstances that change the usual approach.

Texture can precede colour

Palpable follicular roughness may reveal PRP in deeply pigmented skin before orange-red change is obvious. Compare involved skin directly with a spared island.

Islands are high-value clues

Normal skin embedded within confluent plaques is memorable and useful, but psoriasis and other erythrodermas can occasionally mimic it, so histology and course still matter.

No confirmatory blood test

Laboratory abnormalities in extensive disease measure physiological loss or treatment safety. They should not be presented as a diagnostic PRP panel.

Natural history varies

Classic adult disease often remits within years, while atypical adult and familial juvenile disease can persist. Prognosis should follow subtype and observed course.

Rare disease invites anchoring

Once PRP is suggested, clinicians can overlook drug reaction, lymphoma or infection. Each major change deserves a fresh differential rather than automatic escalation.

11Common pitfallsFrequent interpretation and management errors.
  1. 01

    Requiring obvious orange-red colour and missing PRP morphology in deeply pigmented skin.

  2. 02

    Calling every erythroderma psoriasis without looking for follicular papules, spared islands, drug timing, nodes and palmoplantar keratoderma.

  3. 03

    Waiting for histology before stabilising shivering, oliguria or abnormal observations in extensive disease.

  4. 04

    Presenting acitretin or biologic therapy as a universally licensed PRP regimen rather than specialist off-label treatment with limited evidence.

  5. 05

    Ignoring walking and hand function because the affected palmoplantar surface area is small.

  6. 06

    Using emollient extensively without explaining persistent fabric fire risk.

Practice

Two practice questions

Question 1 of 20 correct
DermatologyOriginal SBA

Pattern suggesting PRP

An adult develops rough follicular papules that merge into widespread warm-brown scaly plaques, with sharply defined islands of unaffected skin and waxy fissured palms. Which diagnosis is most likely?

Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom